Pilot Study To Assess The Efficacy & Safety Of H.P. Acthar Gel In Subjects With Relapsing-Remitting Multiple Sclerosis
Posted Date: Aug 27, 2019
- Investigator: Lawrence Goldstick
- Specialties: Multiple Sclerosis, Neurology
- Type of Study: Drug
This is a multicenter, multiple dose study to estimate the response rate, and examine the safety of H.P. Acthar Gel (Acthar) in subjects with RRMS who have not responded to high dose steroids.
Criteria:
Subjects With Rrms Who Have Experienced A Relapse And Who Will Receive 3 To 5 (Given Over A Period Of Up To 7 Days) Days Of Treatment With High Dose Steroids (Oral Or Iv) Within 28 Days Of The Onset Of Relapse Symptoms Are Candidates For The Current Study.
Keywords:
Relapsing-Remitting Multiple Sclerosis, Rrms, Ms
For More Information:
Sarah Hiti
937-535-5013
hitism@ucmail.uc.edu